NasdaqGM - Delayed Quote USD

Orchestra BioMed Holdings, Inc. (OBIO)

4.3900 -0.0500 (-1.13%)
At close: April 26 at 4:00 PM EDT
4.3900 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,760.0000
2,760.0000
3,533.0000
-782.0000
5,703.0000
Cost of Revenue
186.0000
186.0000
211.0000
199.0000
145.0000
Gross Profit
2,574.0000
2,574.0000
3,322.0000
-981.0000
5,558.0000
Operating Expense
54,080.0000
54,080.0000
35,979.0000
20,818.0000
24,310.0000
Operating Income
-51,506.0000
-51,506.0000
-32,657.0000
-21,799.0000
-18,752.0000
Net Non Operating Interest Income Expense
3,849.0000
3,849.0000
50.0000
-927.0000
331.0000
Other Income Expense
-1,463.0000
-1,463.0000
-1,001.0000
-288.0000
-2,934.0000
Pretax Income
-49,120.0000
-49,120.0000
-33,608.0000
-23,014.0000
-21,355.0000
Net Income Common Stockholders
-49,120.0000
-49,120.0000
-33,608.0000
-23,014.0000
-21,355.0000
Diluted NI Available to Com Stockholders
-49,120.0000
-49,120.0000
-33,608.0000
-23,014.0000
-21,355.0000
Basic EPS
-1.48
--
-1.06
-0.73
-0.68
Diluted EPS
-1.48
--
-1.06
-0.73
-0.68
Basic Average Shares
33,225.2270
--
31,614.0790
31,614.0790
31,614.0790
Diluted Average Shares
33,225.2270
--
31,614.0790
31,614.0790
31,614.0790
Total Operating Income as Reported
-51,506.0000
-51,506.0000
-32,657.0000
-21,799.0000
-18,752.0000
Total Expenses
54,266.0000
54,266.0000
36,190.0000
21,017.0000
24,455.0000
Net Income from Continuing & Discontinued Operation
-49,120.0000
-49,120.0000
-33,608.0000
-23,014.0000
-21,355.0000
Normalized Income
-47,657.0000
-47,657.0000
-32,607.0000
-22,726.0000
-18,421.0000
Interest Income
3,849.0000
3,849.0000
50.0000
--
331.0000
Interest Expense
--
--
--
927.0000
--
Net Interest Income
3,849.0000
3,849.0000
50.0000
-927.0000
331.0000
EBIT
-51,506.0000
-51,506.0000
-32,657.0000
-22,087.0000
-18,752.0000
EBITDA
-51,219.0000
-51,219.0000
-32,435.0000
-21,906.0000
-18,615.0000
Reconciled Cost of Revenue
186.0000
186.0000
211.0000
199.0000
145.0000
Reconciled Depreciation
287.0000
287.0000
222.0000
181.0000
137.0000
Net Income from Continuing Operation Net Minority Interest
-49,120.0000
-49,120.0000
-33,608.0000
-23,014.0000
-21,355.0000
Total Unusual Items Excluding Goodwill
-1,463.0000
-1,463.0000
-1,001.0000
-288.0000
-2,934.0000
Total Unusual Items
-1,463.0000
-1,463.0000
-1,001.0000
-288.0000
-2,934.0000
Normalized EBITDA
-49,756.0000
-49,756.0000
-31,434.0000
-21,618.0000
-15,681.0000
12/31/2020 - 8/4/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CDT Conduit Pharmaceuticals Inc.
3.1700
+0.32%
 
SIGY Sigyn Therapeutics, Inc.
6.34
+10.26%
 
SPAGO.ST Spago Nanomedical AB (publ)
0.3600
+0.56%
 
6955.HK Shandong Boan Biotechnology Co., Ltd.
10.000
+1.01%
 
XCUR Exicure, Inc.
0.5001
-1.56%
 
SNTI Senti Biosciences, Inc.
0.2900
+4.05%
 
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
168.000
+9.16%
 
IVBXF Innovent Biologics, Inc.
5.0000
+2.25%
 
TVGNW Tevogen Bio Holdings Inc.
0.0525
+4.79%
 
HRGN Harvard Apparatus Regenerative Technology Inc.
2.3900
0.00%